+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Glioblastoma - Market Insights, Epidemiology and Market Forecast-2028

  • ID: 4790891
  • Drug Pipelines
  • February 2019
  • Region: Global
  • 213 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • ABBVIE
  • BRISTOL-MYERS SQUIBB
  • CELGENE
  • DIFFUSION PHARMACEUTICALS
  • GENENTECH
  • MERCK
  • MORE
‘Glioblastoma - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Glioblastoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Glioblastoma from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Glioblastoma - Disease Understanding and Treatment Algorithm

Glioblastoma (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations. There is a remarkable development in GBM because it occurs via a complex network of various different molecular and genetic aberrations, which leads to significant changes in major signaling pathways. GBMs, as they extensively disperse throughout the parenchyma, making maximal surgical resection unattainable and having high level of vascularization, are lethal in nature

GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions. While GBM is highly locally invasive (invading normal brain tissue), it rarely spreads to other organs beyond the brain. A highly aggressive, fast-growing cancer and treatment is often limited by the tumor location and the ability of a patient to tolerate surgery. Consequently, it is a particularly difficult cancer to treat

The Glioblastoma market report gives the thorough understanding of the Glioblastoma by including details such as disease definition, classification, types, symptoms, pathophysiology, inheritance, molecular classification diagnostic trends. It also provides treatment algorithms and treatment guidelines for Glioblastoma in the US, Europe, and Japan

Glioblastoma Epidemiology

The Glioblastoma epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of Glioblastoma, Total Diagnosed Incident Population of Glioblastoma, Gender specific Diagnosed Incidence of Glioblastoma, Type specific Diagnosed Incidence of Glioblastoma and Incident Population of Associated Comorbidities in Glioblastoma scenario of Glioblastoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028

According to this research, incident population of Glioblastoma associated with menopause in 7MM countries is expected to increase at a CAGR of 1.11% for the study period i.e. 2017-2028. As per the estimates, United States has the highest incident population of Glioblastoma. Among the European countries, UK had the highest incident population of Glioblastoma with 3,492 cases, followed by France which had incident population of 2,683 in 2017

Glioblastoma Drug Chapters

This segment of the Glioblastoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases

The current therapeutic landscape of Glioblastoma in the report provides the detailed chapters of upcoming therapies such as late-stage therapies including Marizomib (Celgene), VAL-083 (DelMar Pharmaceuticals), JP0001 (Johnpro Biotech), and many more with the mid-stage products like Enzastaurin Hydrochloride (Denovo Biopharma; Eli Lilly), ALECSAT (CytoVac) and others, which are expected to launch during the forecast period [2019-2028] have also been covered in the report

Glioblastoma Market Outlook

The Glioblastoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight

According to this research, the market size of Glioblastoma in the seven major markets is expected to reach around USD 2,306 million by 2028. The United States accounts for the highest market size of Glioblastoma in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Expected Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed incident population of Glioblastoma Multiforme. Owing to the positive outcomes of the several products during the developmental stage by key players such as DelMar Pharmaceuticals, Abbvie, Diffusion Pharmaceuticals, Tocagen, Apogenix etc. has a potential to create a significant positive shift in the Glioblastoma market size. The research analysts estimate that the market is expected to show positive growth post 2022, due to the increased patient incidence and to the expected launch of emerging therapies

Glioblastoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions

Expected launch of therapies for Glioblastoma such as Celgene’s Marizomib, DelMar’s VAL-083, Green Cross Cell’s Immuncell-LC and other targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Glioblastoma market

Glioblastoma Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Glioblastoma Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake
Glioblastoma Report Assessment
  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Glioblastoma market
  • Organize sales and marketing efforts by identifying the best opportunities for Glioblastoma market
  • To understand the future market competition in the Glioblastoma market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ABBVIE
  • BRISTOL-MYERS SQUIBB
  • CELGENE
  • DIFFUSION PHARMACEUTICALS
  • GENENTECH
  • MERCK
  • MORE
1 KEY INSIGHTS

2 GLIOBLASTOMA MULTIFORME MARKET OVERVIEW AT A GLANCE
2.1 MARKET SHARE (%) DISTRIBUTION OF GLIOBLASTOMA MULTIFORME IN 2017
2.2 MARKET SHARE (%) DISTRIBUTION OF GLIOBLASTOMA MULTIFORME IN 2028

3 DISEASE BACKGROUND AND OVERVIEW: GLIOBLASTOMA MULTIFORME (GBM)
3.1 INTRODUCTION
3.2 CLASSIFICATION OF GLIOBLASTOMA MULTIFORME
3.3 GLIOBLASTOMA TYPES
3.3.1 Astrocytomas
3.3.2 Ependymomas
3.3.3 Oligodendrogliomas
3.3.4 Mixed gliomas
3.3.5 Optic pathway gliomas
3.4 SYMPTOMS
3.5 PATHOPHYSIOLOGY
3.5.1 Macroscopic and Histological Features of GBM
3.5.2 Genetic and Molecular Pathogenesis
3.6 INHERITANCE OF GLIOBLASTOMA MULTIFORME
3.6.1 Genetic Variations of Glioblastoma Multiforme
3.7 MOLECULAR CLASSIFICATION
3.7.1 Specific Molecular Biomarkers
3.8 DIAGNOSIS OF GLIOBLASTOMA MULTIFORME
3.8.1 Neurological Exams
3.8.2 Angiograms
3.8.3 Magnetic resonance imaging (MRI) and computerized Tomography (CT)
3.8.4 Perfusion MRI
3.8.5 MR spectroscopy
3.8.6 Histological Diagnosis
3.8.7 Surgical Biopsy
3.9 GLIOBLASTOMA IN NUT SHELL

4 EPIDEMIOLOGY AND PATIENT POPULATION
4.1 KEY FINDINGS
4.2 7MM TOTAL PATIENT POPULATION OF GLIOBLASTOMA MULTIFORME
4.1 7MM TOTAL DIAGNOSED PATIENT POPULATION OF GLIOBLASTOMA MULTIFORME

5 COUNTRY WISE-EPIDEMIOLOGY OF GLIOBLASTOMA MULTIFORME
5.1 UNITED STATES
5.1.1 Assumptions and Rationale
5.1.2 Total Incident Population of Glioblastoma Multiforme in the United States
5.1.3 Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States
5.1.4 Gender specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
5.1.5 Type specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
5.1.6 Incident Population of Associated Comorbidities in Glioblastoma Multiforme in the United States
5.2 EU5 COUNTRIES
5.2.1 Assumptions and Rationale
5.3 GERMANY
5.3.1 Total Incident Population of Glioblastoma Multiforme in Germany
5.3.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany
5.3.3 Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
5.3.4 Type specific Diagnosed Incidence of Glioblastoma Multiforme in Germany
5.3.5 Incident Population of Associated Comorbidities in Glioblastoma Multiforme in Germany
5.4 FRANCE
5.4.1 Total Incident Population of Glioblastoma Multiforme in France
5.4.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in France
5.4.3 Gender specific Diagnosed Incidence of Glioblastoma Multiforme in the United States
5.4.4 Type specific Diagnosed Incidence of Glioblastoma Multiforme in France
5.4.5 Incident Population of Associated Comorbidities in Glioblastoma Multiforme in France
5.5 ITALY
5.5.1 Total Incident Population of Glioblastoma Multiforme in Italy
5.5.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy
5.5.3 Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
5.5.4 Type specific Diagnosed Incidence of Glioblastoma Multiforme in Italy
5.5.5 Incident Population of Associated Comorbidities in Glioblastoma Multiforme in Italy
5.6 SPAIN
5.6.1 Total Incident Population of Glioblastoma Multiforme in Spain
5.6.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain
5.6.3 Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
5.6.4 Type specific Diagnosed Incidence of Glioblastoma Multiforme in Spain
5.6.5 Incident Population of Associated Comorbidities in Glioblastoma Multiforme in Spain
5.7 UNITED KINGDOM
5.7.1 Total Incident Population of Glioblastoma Multiforme in the United Kingdom
5.7.2 Total Diagnosed Incident Population of Glioblastoma Multiforme in the United Kingdom
5.7.3 Gender specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
5.7.4 Type specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom
5.7.5 Incident Population of Associated Comorbidities in Glioblastoma Multiforme in the United Kingdom
5.8 JAPAN
5.8.1 Assumptions and Rationale
5.8.2 Total Incident Population of Glioblastoma Multiforme in Japan
5.8.3 Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan
5.8.4 Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
5.8.5 Type specific Diagnosed Incidence of Glioblastoma Multiforme in Japan
5.8.6 Incident Population of Associated Comorbidities in Glioblastoma Multiforme in Japan

6 TREATMENT
6.1 SURGERY
6.2 CHEMOTHERAPY
6.3 RADIATION
6.4 OTHERS
6.4.1 Targeted therapy
6.4.2 Tumor treatment fields (TTF)
6.4.3 Immunotherapy
6.5 MANAGEMENT OF SYMPTOMS WITH MEDICATION

7 TREATMENT ALGORITHM

8 UNMET NEEDS

9 MARKETED DRUGS
9.1 AVASTIN: GENENTECH
9.1.1 Drug Description
9.1.2 Regulatory Milestones
9.1.3 Other Development Activities
9.1.4 Safety and Efficacy
9.1.5 Product Profile
9.2 TEMODAR/TEMODAL: MERCK
9.2.1 Drug Description
9.2.2 Regulatory Milestones
9.2.3 Other Development Activities
9.2.4 Safety and Efficacy
9.2.5 Product Profile

10 EMERGING DRUGS
10.1 KEY CROSS COMPETITION (LATE-STAGE EMERGING DRUGS)
10.2 KEY CROSS COMPETITION (MID-STAGE EMERGING DRUGS)
10.3 CAR-T IMMUNOTHERAPY DEVELOPMENT PRODUCTS
10.4 IMMUNCELL-LC: GREEN CROSS CELL CORPORATION
10.4.1 Product Description
10.4.2 Other Development Activities
10.4.3 Clinical Development
10.4.4 Product Profile
10.5 MARIZOMIB: CELGENE
10.5.1 Product Description
10.5.2 Other Development Activities
10.5.3 Clinical Development
10.5.4 Product Profile
10.6 DIANHYDROGALACTITOL (VAL-083): DELMAR PHARMACEUTICALS
10.6.1 Product Description
10.6.2 Other Development Activities
10.6.3 Clinical Development
10.6.4 Product Profile
10.7 OFRANERGENE OBADENOVEC (VB-111): VBL THERAPEUTICS
10.7.1 Product Description
10.7.2 Other Development Activities
10.7.3 Clinical Development
10.7.4 Product Profile
10.8 DEPATUXIZUMAB MAFODOTIN (ABT-414): ABBVIE
10.8.1 Product Description
10.8.2 Other Development Activities
10.8.3 Clinical Development
10.8.4 Safety and Efficacy
10.8.5 Product Profile
10.9 TRANS SODIUM CROCETINATE: DIFFUSION PHARMACEUTICALS
10.9.1 Product Description
10.9.2 Other Development Activities
10.9.3 Clinical Development
10.9.4 Safety and Efficacy
10.9.5 Product Profile
10.10 SIROQUINE (JP001): JOHNPRO BIOTECH
10.10.1 Product Description
10.10.2 Other Development Activities
10.10.3 Clinical Development
10.10.4 Product Profile
10.11 NIVOLUMAB: BRISTOL-MYERS SQUIBB/ONO PHARMACEUTICALS
10.11.1 Product Description
10.11.2 Other Development Activities
10.11.3 Clinical Development
10.11.4 Safety and Efficacy
10.11.5 Product Profile
10.12 IPILIMUMAB: BRISTOL-MYERS SQUIBB
10.12.1 Product Description
10.12.2 Other Development Activities
10.12.3 Clinical Development
10.12.4 Safety and Efficacy
10.12.5 Product Profile
10.13 ASUNERCEPT: APOGENIX
10.13.1 Product Description
10.13.2 Other Development Activities
10.13.3 Clinical Development
10.13.4 Product Profile
10.14 TOCA 511 AND TOCA FC: TOCAGEN
10.14.1 Product Description
10.14.2 Other Development Activities
10.14.3 Clinical Development
10.14.4 Product Profile
10.15 TASADENOTUREV: DNATRIX
10.15.1 Product Description
10.15.2 Other Development Activities
10.15.3 Clinical Development
10.15.4 Product Profile

11 GLIOBLASTOMA MULTIFORME: 7 MAJOR MARKET ANALYSIS
11.1 KEY FINDINGS
11.2 MARKET SIZE OF GLIOBLASTOMA MULTIFORME IN 7MM

12 THE UNITED STATES MARKET OUTLOOK
12.1 UNITED STATES MARKET SIZE
12.1.1 Total Market size of Glioblastoma Multiforme
12.1.2 Market Size by Therapies

13 EU-5 COUNTRIES: MARKET OUTLOOK
13.1 GERMANY
13.1.1 Total Market size of Glioblastoma Multiforme in Germany
13.1.2 Market Size by Therapies
13.2 FRANCE
13.2.1 Total Market Size of Glioblastoma Multiforme
13.2.2 Market Size by Therapies
13.3 ITALY
13.3.1 Total Market Size of Glioblastoma Multiforme
13.3.2 Market Size by Therapies
13.4 SPAIN
13.4.1 Total Market Size of Glioblastoma Multiforme
13.4.2 Market Size by Therapies
13.5 UNITED KINGDOM
13.5.1 Total Market Size of Glioblastoma Multiforme
13.5.2 Market Size by Therapies

14 JAPAN: MARKET OUTLOOK
14.1 JAPAN MARKET SIZE
14.1.1 Total Market Size of Glioblastoma Multiforme
14.1.2 Market Size by Therapies

15 MARKET DRIVERS

16 MARKET BARRIERS

17 APPENDIX
17.1 REPORT METHODOLOGY

18 Publisher Capabilities

19 DISCLAIMER

20 About the Publisher

List of Tables
Table 1: Total Population of Glioblastoma Multiforme in the 7MM (2017-2028)
Table 2: Total Diagnosed Population of Glioblastoma Multiforme in the 7MM (2017-2028)
Table 3: Total Incident Population of Glioblastoma Multiforme in the United States (2017-2028)
Table 4: Total Diagnosed Incidence Population of Glioblastoma Multiforme in the United States (2017-2028)
Table 5: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017-2028)
Table 6: Type specific Diagnosed Incidence of GBM in the United States (2017-2028)
Table 7: Incident Population of Associated Comorbidities in GBM in the United States (2017-2028)
Table 8: Total Incident Population of Glioblastoma Multiforme in Germany (2017-2028)
Table 9: Total Diagnosed Incidence Population of Glioblastoma Multiforme in Germany (2017-2028)
Table 10: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017-2028)
Table 11: Type specific Diagnosed Incidence of GBM in Germany (2017-2028)
Table 12: Incident Population of Associated Comorbidities in GBM in Germany (2017-2028)
Table 13: Total Incident Population of Glioblastoma Multiforme in France (2017-2028)
Table 14: Total Diagnosed Incidence Population of Glioblastoma Multiforme in France (2017-2028)
Table 15: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017-2028)
Table 16: Type specific Diagnosed Incidence of GBM in France (2017-2028)
Table 17: Incident Population of Associated Comorbidities in GBM in France (2017-2028)
Table 18: Total Incident Population of Glioblastoma Multiforme in Italy (2017-2028)
Table 19: Total Diagnosed Incidence Population of Glioblastoma Multiforme in Italy (2017-2028)
Table 20: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017-2028)
Table 21: Type specific Diagnosed Incidence of GBM in Italy (2017-2028)
Table 22: Incident Population of Associated Comorbidities in GBM in Italy (2017-2028)
Table 23: Total Incident Population of Glioblastoma Multiforme in Spain (2017-2028)
Table 24: Total Diagnosed Incidence Population of Glioblastoma Multiforme in Spain (2017-2028)
Table 25: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Spain 2017-2028)
Table 26: Type specific Diagnosed Incidence of GBM in Spain (2017-2028)
Table 27: Incident Population of Associated Comorbidities in GBM in Spain (2017-2028)
Table 28: Total Incident Population of Glioblastoma Multiforme in the United Kingdom (2017-2028)
Table 29: Total Diagnosed Incidence Population of Glioblastoma Multiforme in the United Kingdom (2017-2028)
Table 30: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017-2028)
Table 31: Type specific Diagnosed Incidence of GBM in the UK (2017-2028)
Table 32: Incident Population of Associated Comorbidities in GBM in the UK(2017-2028)
Table 33: Total Incident Population of Glioblastoma Multiforme in Japan (2017-2028)
Table 34: Total Diagnosed Incidence Population of Glioblastoma Multiforme in Japan (2017-2028)
Table 35: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017-2028)
Table 36: Type specific Diagnosed Incidence of GBM in Japan (2017-2028)
Table 37: Incident Population of Associated Comorbidities in GBM in Japan (2017-2028)
Table 38: Comparison of Late-Stage emerging drugs under development
Table 39: Comparison of Mid-Stage emerging drugs
Table 40: Poducts under development by Chimeric Antigen Receptor (CAR) T cell Immunotherapy
Table 41: Clinical Trial Description
Table 42: Clinical Trial Description
Table 43: Clinical Trial Description
Table 44: Clinical Trial Description
Table 45: Clinical Trial Description
Table 46: Clinical Trial Description
Table 47: Clinical Trial Description
Table 48: Clinical Trial Description
Table 49: Clinical Trial Description
Table 50: 7 Major Market Size of Glioblastoma Multiforme in USD Million (2017-2028)
Table 51: United States Market Size of Glioblastoma Multiforme in US, USD Million (2017-2028)
Table 52: Market size of Glioblastoma Multiforme by therapies in United States, in USD Million (2017-2028)
Table 53: Market Size of Glioblastoma Multiforme in Germany, in USD Million (2017-2028)
Table 54: Market size of Glioblastoma Multiforme by therapies in Germany, in USD Million (2017-2028)
Table 55: Market Size of Glioblastoma Multiforme in France, in USD Million (2017-2028)
Table 56: Market size of Glioblastoma Multiforme by therapies in France, in USD Million (2017-2028)
Table 57: Market Size of Glioblastoma Multiforme in Italy, in USD Million (2017-2028)
Table 58: Market size of Glioblastoma Multiforme by therapies in Italy, in USD Million (2017-2028)
Table 59: Market Size of Glioblastoma Multiforme in Spain, in USD Million (2017-2028)
Table 60: Market size of Glioblastoma Multiforme by therapies in Spain, in USD Million (2017-2028)
Table 61: Market Size of Glioblastoma Multiforme in the UK, in USD Million (2017-2028)
Table 62: Market size of Glioblastoma Multiforme by therapies in the UK, in USD Million (2017-2028)
Table 63: Market Size of Glioblastoma Multiforme in Japan, in USD Million (2017-2028)
Table 64: Market size of Glioblastoma Multiforme by therapies in Japan, in USD Million (2017-2028)

List of Figures
Figure 1: Classification of Glioblastoma
Figure 2: Different types of Glioblastoma
Figure 3: Generalized transcription pathways related to Glioblastoma disease
Figure 4: Up-regulated Genetic Pathways in Glioblastoma
Figure 5: Overall pathways of IDH mutations
Figure 6: Chemistry of O6-Methylguanine-DNA Methyltransferase (MGMT)
Figure 7: Functioning of MicroRNA as a biomarker in Glioblastoma
Figure 8: Total Patient Population of Glioblastoma Multiforme in the 7MM (2017-2028)
Figure 9: Total Incidence of Glioblastoma Multiforme in the United States (2017-2028)
Figure 10: Total Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017-2028)
Figure 11: Gender specific Diagnosed Incidence of GBM in the United States (2017-2028)
Figure 12: Type specific Diagnosed Incidence of Glioblastoma Multiforme in the United States (2017-2028)
Figure 13: Incident Population of Associated Comorbidities in GBM in the US (2017-2028)
Figure 14: Total Incident of Glioblastoma Multiforme in Germany (2017-2028)
Figure 15: Total Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017-2028)
Figure 16: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017-2028)
Figure 17: Type specific Diagnosed Incidence of Glioblastoma Multiforme in Germany (2017-2028)
Figure 18: Incident Population of Associated Comorbidities in GBM in Germany (2017-2028)
Figure 19: Total Incidence of Glioblastoma Multiforme in France (2017-2028)
Figure 20: Total Diagnosed Incidence of Glioblastoma Multiforme in France (2017-2028)
Figure 21: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017-2028)
Figure 22: Type specific Diagnosed Incidence of Glioblastoma Multiforme in France (2017-2028)
Figure 23: Incident Population of Associated Comorbidities in GBM in France (2017-2028)
Figure 24: Total Incidence of Glioblastoma Multiforme in Italy (2017-2028)
Figure 25: Total Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017-2028)
Figure 26: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017-2028)
Figure 27: Type specific Diagnosed Incidence of Glioblastoma Multiforme in Italy (2017-2028)
Figure 28: Incident Population of Associated Comorbidities in GBM in Italy (2017-2028)
Figure 29: Total Incidence of Glioblastoma Multiforme in Spain (2017-2028)
Figure 30: Total Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017-2028)
Figure 31: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017-2028)
Figure 32: Type specific Diagnosed Incidence of Glioblastoma Multiforme in Spain (2017-2028)
Figure 33: Incident Population of Associated Comorbidities in GBM in Spain (2017-2028)
Figure 34: Total Incidence of Glioblastoma Multiforme in the United Kingdom (2017-2028)
Figure 35: Total Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom (2017-2028)
Figure 36: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017-2028)
Figure 37: Type specific Diagnosed Incidence of Glioblastoma Multiforme in the UK (2017-2028)
Figure 38: Incident Population of Associated Comorbidities in GBM in the UK (2017-2028)
Figure 39: Total Incidence of Glioblastoma Multiforme in Japan (2017-2028)
Figure 40: Total Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017-2028)
Figure 41: Gender specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017-2028)
Figure 42: Type specific Diagnosed Incidence of Glioblastoma Multiforme in Japan (2017-2028)
Figure 43: Incident Population of Associated Comorbidities in GBM in Japan (2017-2028)
Figure 44: Unmet Needs of Glioblastoma Multiforme
Figure 45: 7 Major Market Size of Glioblastoma Multiforme in USD Million (2017-2028)
Figure 46: Market Size of Glioblastoma Multiforme in the United States, USD Millions (2017-2028)
Figure 47: Market size of Glioblastoma Multiforme by therapies in the US, in USD Million (2017-2028)
Figure 48: Market Size of Glioblastoma Multiforme in Germany, USD Million (2017-2028)
Figure 49: Market Size of Glioblastoma Multiforme by therapies, in Germany, in USD Million (2017-2028)
Figure 50: Market Size of Glioblastoma Multiforme in France, USD Million (2017-2028)
Figure 51: Market Size of Glioblastoma Multiforme by therapies, in France, in USD Million (2017-2028)
Figure 52: Market Size of Glioblastoma Multiforme in Italy, USD Million (2017-2028)
Figure 53: Market Size of Glioblastoma Multiforme by therapies in Italy, in USD Million (2017-2028)
Figure 54: Market Size of Glioblastoma Multiforme in Spain, USD Million (2017-2028)
Figure 55: Market Size of Glioblastoma Multiforme by therapies in Spain, in USD Million (2017-2028)
Figure 56: Market Size of Glioblastoma Multiforme in the UK, USD Million (2017-2028)
Figure 57: Market Size of Glioblastoma Multiforme by therapies in the UK, in USD Million (2017-2028)
Figure 58: Market Size of Glioblastoma Multiforme in Japan, USD Million (2017-2028)
Figure 59: Market Size of Glioblastoma Multiforme by therapies in Japan, in USD Million (2017-2028)
Figure 60: Market Drivers
Figure 61: Market Barriers
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • GENENTECH
  • MERCK
  • GREEN CROSS CELL CORPORATION
  • CELGENE
  • DELMAR PHARMACEUTICALS
  • VBL THERAPEUTICS
  • ABBVIE
  • DIFFUSION PHARMACEUTICALS
  • JOHNPRO BIOTECH
  • BRISTOL-MYERS SQUIBB
  • ONO PHARMACEUTICALS
  • BRISTOL-MYERS SQUIBB
  • APOGENIX
  • TOCAGEN
  • DNATRIX
Note: Product cover images may vary from those shown
Adroll
adroll